【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 29
3.1.3 Basic Breast Anatomy 30
3.2 Disease Classification/Staging Systems 31
3.3 Symptoms 33
3.4 Prognosis 33
3.5 Quality of Life 34
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 37
4.2.1 A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk 39
4.2.2 Reproductive hormonal factors influence the risk of breast cancer 39
4.2.3 Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients 41
4.2.4 Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks 43
4.3 Global Trends 46
4.3.1 Incidence 46
4.3.2 Prevalence and Survival 52
4.4 Forecast Methodology 56
4.4.1 Sources Used 58
4.4.2 Sources Not Used 62
4.4.3 Forecast Assumptions and Methods 63
4.5 Epidemiological Forecast for Breast Cancer (2013-2023) – Diagnosed Incident Cases 66
4.5.1 Diagnosed Incident Cases of Breast Cancer 66
4.5.2 Diagnosed Incident Cases of Breast Cancer by Age 68
4.5.3 Diagnosed Incident Cases of Breast Cancer by Menopausal Status 70
4.5.4 Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis 72
4.5.5 Age-Standardized Diagnosed Incidence Rate of Breast Cancer 73
4.6 Epidemiological Forecast for Breast Cancer (2013-2023) — Diagnosed Prevalent Cases 74
4.6.1 Five-Year Diagnosed Prevalent Cases of Breast Cancer 74
4.6.2 Five-Year Diagnosed Prevalent Cases by Menopausal Status 76
4.6.3 Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes 77
4.7 Discussion 79
4.7.1 Epidemiological Forecast Insight 79
4.7.2 Limitations of the Analysis 81
4.7.3 Strengths of the Analysis 82
5 Disease Management 84
5.1 Diagnosis and Treatment Overview 84
5.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 84
5.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC) 86
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 90
5.2 US 91
5.2.1 Diagnosis 91
5.2.2 Clinical Practice 92
5.3 France 95
5.3.1 Diagnosis 95
5.3.2 Clinical Practice 96
5.4 Germany 99
5.4.1 Diagnosis 99
5.4.2 Clinical Practice 100
5.5 Italy 103
5.5.1 Diagnosis 103
5.5.2 Clinical Practice 104
5.6 Spain 106
5.6.1 Diagnosis 106
5.6.2 Clinical Practice 107
5.7 UK 110
5.7.1 Diagnosis 110
5.7.2 Clinical Practice 111
5.8 Japan 114
5.8.1 Diagnosis 114
5.8.2 Clinical Practice 115
5.9 China 117
5.9.1 Diagnosis 117
5.9.2 Clinical Practice 119
6 Competitive Assessment 122
6.1 Overview 122
6.2 Product Profiles (Branded Therapies) 123
6.2.1 Abraxane (nab-paclitaxel) 123
6.2.2 Afinitor (everolimus) 128
6.2.3 Avastin (bevacizumab) 133
6.2.4 Doxil/Caelyx (pegylated liposomal doxorubicin) 137
6.2.5 Halaven (eribulin mesylate) 142
6.2.6 Ixempra (ixabepilone) 145
6.2.7 Xeloda (capecitabine) 148
6.3 Product Profiles (Hormonal Agents) 151
6.3.1 Tamoxifen 151
6.3.2 Faslodex (fulvestrant) 151
6.3.3 Aromatase Inhibitors 152
7 Unmet Need and Opportunity 156
7.1 Overview 156
7.1.1 Defined treatment plan for BRCA mutation-positive patients and prevention of prophylactic surgeries 158
7.1.2 Specific treatment options for TNBC patients 160
7.1.3 Prevention of brain metastasis 161
7.1.4 Neoadjuvant therapy that can downstage tumors 163
7.1.5 For HR+patients, reduced resistance to hormonal agents 164
7.1.6 Improved convenience of administration of hormonal agents 166
8 Pipeline Assessment 168
8.1 Overview 168
8.1.1 Abemaciclib (LY2835219) 169
8.1.2 Buparlisib (BKM- 120) 175
8.1.3 Javlor (vinflunine) 181
8.1.4 LEE011 185
8.1.5 NeuVax (nelipepimut-S/E75) 190
8.1.6 Niraparib (MK4827) 195
8.1.7 NKTR- 102 (etirinotecan pegol) 200
8.1.8 Lynparza (olaparib) 204
8.1.9 Palbociclib (PD-0332991) 209
8.1.10 Talazoparib (BMN 673) 215
8.1.11 Veliparib (ABT-888) 219
8.2 Promising Drugs in Clinical Development 224
8.2.1 PD-/PD-L 1 Immunotherapies 225
9 Current and Future Players 227
9.1 Overview 227
9.2 Trends in Corporate Strategy 229
9.3 Company Profiles 232
9.3.1 AstraZeneca 232
9.3.2 Bristol-Myers Squibb 233
9.3.3 Eli Lilly 235
9.3.4 Pfizer 236
9.3.5 Novartis/GlaxoSmithKline 239
10 Market Outlook 241
10.1 Global Markets 241
10.1.1 Forecast 241
10.1.2 Drivers and Barriers – Global Issues 247
10.2 US 249
10.2.1 Forecast 249
10.2.2 Key Events 252
10.2.3 Drivers and Barriers 253
10.3 France 255
10.3.1 Forecast 255
10.3.2 Key Events 258
10.3.3 Drivers and Barriers 259
10.4 Germany 260
10.4.1 Forecast 260
10.4.2 Key Events 264
10.4.3 Drivers and Barriers 265
10.5 Italy 266
10.5.1 Forecast 266
10.5.2 Key Events 270
10.5.3 Drivers and Barriers 271
10.6 Spain 272
10.6.1 Forecast 272
10.6.2 Key Events 275
10.6.3 Drivers and Barriers 276
10.7 UK 277
10.7.1 Forecast 277
10.7.2 Key Events 281
10.7.3 Drivers and Barriers 282
10.8 Japan 284
10.8.1 Forecast 284
10.8.2 Key Events 287
10.8.3 Drivers and Barriers 288
10.9 China 289
10.9.1 Forecast 289
10.9.2 Key Events 292
10.9.3 Drivers and Barriers 292
11 Appendix 294
11.1 Bibliography 294
11.2 Abbreviations 321
11.3 Methodology 329
11.4 Forecasting Methodology 329
11.4.1 Diagnosed HER2-Negative Breast Cancer Patients 329
11.4.2 Percentage of Drug-Treated Patients 330
11.4.3 Drugs Included in Each Therapeutic Class 330
11.4.4 Launch and Patent Expiry Dates 331
11.4.5 General Pricing Assumptions 332
11.4.6 Individual Drug Assumptions 334
11.4.7 Generic Erosion 342
11.4.8 Pricing of Pipeline Agents 342
11.5 Primary Research – KOLs Interviewed for This Report 353
11.6 Primary Research – High-Prescriber Survey 355
11.7 About the Authors 356
11.7.1 Analyst 356
11.7.2 Director of Oncology 356
11.7.3 Epidemiologist 357
11.7.4 Director of Epidemiology 357
11.7.5 Global Head of Healthcare 358
11.8 About GlobalData 359
11.9 Disclaimer 359
【レポート販売概要】
■ タイトル：HER2陰性乳癌治療薬の世界市場予測および分析■ 英文：PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
■ 発行日：2015年1月31日
■ 調査会社：GlobalData
■ 商品コード：GDHC92PIDR
■ 調査対象地域：グローバル
- 非プロトン性溶媒の世界市場の規模及び予測：製品別（NMP、トルエン、ベンゼン、アセトン）、用途別（石油・ガス、医薬品、塗料・コーティング、電子製品）、地域別（北アメリカ、ヨーロッパ、アジア太平洋、CSA、MEA）、動向の分析 2014-2025The global aprotic solvents market is projected to reach USD 21.79 Billion by 2025, according to a new report by Grand View Research, Inc. Growing pharmaceuticals industry is expected to drive the market over the forecast period. In 2015, toluene dominated the product segment courtesy growing demand from end-use industries such as paints & coatings and construction. Toluene is also used in the man …
- Soluscope SAS：市場シェア分析Soluscope SAS Market Share Analysis Summary GlobalData’s new report, “Soluscope SAS Market Share Analysis” provides in-depth information on Soluscope SAS’s market position in the different medical equipment markets it operates in. The report provides Soluscope SAS market share information in one key market category – Endoscopic reprocessors. The report also provides data and information on the ove …
- Petrichor Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- 2012Petrichor Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary Petrichor Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
- 世界のスマート照明市場機会分析In the past 18 months, the smart lighting business has taken important new directions, creating opportunities at every level of the lighting value chain. As NanoMarkets has predicted for several years now, smart lighting vendors now see their value proposition as having more to do with mood lighting than lighting efficiency. In addition, smart lighting is now conceived of as part of the Internet-o …
- スマートe-Drive（イードライブ）の世界市場予測（～2022年）：パワーエレクトロニクス、Eブレーキブースター、インバータ、モータ、バッテリー“Increase in demand for green vehicles, overall vehicle weight reduction, and tailpipe emissions reduction to upsurge the demand for smart e-drive systems in the automotive industry”The smart e-drive market for automotive is projected to grow at a CAGR of 32.00% from 2017 to 2022, to reach USD 1,468.2 million by 2022. The demand for an increase in vehicle space is projected to fuel the demand for …
- 花卉園芸の世界市場2018-2022108 pages, November 2018 About this market The use of Instagram as a marketing tool to gain traction in the market. Flowers are sold based on appearances and fragrances. Instagram provides a good platform for sharing attractive pictures of flowers for generating interest among consumers. Technavio’s analysts have predicted that the floriculture market will register a CAGR of almost 6% by 2022. Mar …
- 生鮮食品包装のヨーロッパ市場：果物、野菜、サラダThe Europe fresh food packaging market size was valued at $3,718.2 million in 2017 and is expected to reach $4,890.6 million by 2026, registering a CAGR of 3.1% from 2019 to 2026. Food packaging helps in retardation of product deterioration, retainment of the beneficial effects of processing, helps in extension of shelf-life, and increasing and maintaining the quality and safety of food. European …
- デンドリマーの世界市場2010-2025Dendrimers are widely investigated and utilized in biomedical applications, as they have multiple surface functional groups that can be used to target or label the dendrimer for imaging and drug delivery applications. They have found application in transdermal drug delivery systems and show potential in gene delivery and for enhancing the oral bioavailability of problematic drugs. Their are a numb …
- 世界のサイトメガロウイルス網膜炎治療市場（2014-2018）About Cytomegalovirus Retinitis Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative organism of this disease is cytomegalovirus, a herpes virus that attacks the photosensitive cells in the retina. This disease can lead to permanent blindness if left untreated. It affects one eye initially but spreads to the other eye if neglected. The virus is very commonly found in …
- オーストラリアのビチューメン及びアスファルト市場：貿易（輸入、輸出）動向This market research report examines the foreign trade of Australia and its perspectives on the global market for Bitumen and asphalt, natural. The report will be of considerable interest primarily to relevant strategic planners, senior company officials and importers/exporters, since it features invaluable information on Bitumen and asphalt, natural export/import operations in Australia. The 2002 …
- グローバル鉄道市場におけるトップ10企業分析This report presents key information and issues for all the leading companies in the global railway industry for business intelligence requirements. It also provides information on business operations, history, major products and services, prospects, key competitors, key employees, locations and subsidiaries for the companies featured within the report. In addition, the report also provides streng …
- 世界の国土安全保障及び緊急危機管理市場This report presents a complete analysis of the global homeland security market across the next five years. It analyses about the factors driving the market, the challenges faced by the industry and about the factors restraining the growth of the market. It also discusses the key industry trends, market trends and technology trends that is about to influence the global homeland security market. It …
- アジアの試験測定（T&M）装置市場2015-2019Technavios market research analyst predicts the test and measurement (T&M) equipment market in APAC to grow steadily at a CAGR of nearly 7% until 2019. Factors such as the rapid growth of the communication and semiconductor sectors and an increase in electronic manufacturing activities in APAC will fuel the demand for T&M equipment during the forecast period. Furthermore, with the augmented demand …
- 塩化カリウムの世界市場2017-2021About Potassium ChloridePotassium chloride is a metal halide salt containing potassium and chlorine. It is crystalline in structure and is highly soluble in water. It is vital for plant growth and is mainly used in fertilizer applications. Technavio’s analysts forecast the global potassium chloride market to grow at a CAGR of 3.80% during the period 2017-2021. [Covered in this report] The report c …
- 世界の整形外科用バイオマテリアル（生体材料）市場：移植骨、機械加工骨、DBM、BMP（骨形成タンパク質)などAbout Orthopedic Biomaterial Orthopedic biomaterial deals with the physical and chemical properties of the material that is implanted into the human body as constituents of devices. The material implanted is designed to perform specific biological functions by substituting or repairing the damaged tissues such as cartilage, bone, ligaments, and tendons. Bone and joint-related degenerative problems …
